All In Biotech

Drug Trial Radar · NCT07512947

Study of YKST02 Alone or in Combination With YK012 in Patients With Active or Refractory Systemic Lupus Erythematosus

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Efficacy of YKST02 as Monotherapy or in Combination With YK012 in Patients With Active or Refractory Systemic Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

May 2026

Primary completion

Mar 30, 2028

Study completion Jun 30, 2028

Sponsor

Sponsor type
Academic, hospital or other
First posted
Apr 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YKST02 administered alone or in combination with YK012 in participants with active or refractory systemic lupus erythematosus (SLE). The main questions this study aims to address are: * Whether YKST02 alone or in combination with YK012 is safe and well tolerated in participants with active or refractory SLE * Whether YKST02 alone or in combination with YK012 demonstrates preliminary efficacy in treating SLE * What the PK and PD characteristics of YKST02 are when administered alone or in combination with YK012 * Whether treatment with YKST02 induces anti-drug antibody responses Participants will: * Receive intravenous infusions of YKST02 alone or in combination with YK012 according to the assigned cohort * Undergo safety assessments, including monitoring for adverse events * Provide blood samples for PK, PD, and immunogenicity analyses * Be followed for approximately 49 weeks to assess safety and efficacy

Conditions

  • System Lupus Erythematosus(SLE)

Interventions

  • YKST02Drug

    YKST02 is administered by intravenous (IV) infusion.

  • YK012Drug

    YK012 is administered by intravenous (IV) infusion in combination with YKST02.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose-Limiting Toxicities (DLTs)Time frame: From first dose through Day 35
  2. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From first dose up to Week 49

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.